Efficacy Analysis of Sorafenib Tosylate Combined with TACE in the Treatment of Unresectable Localized Liver Cancer Patients
Objective To investigate the efficacy of sorafenib toluene sulfonate combined with transcatheter arterial che-moembolization(TACE)in patients with unresectable localized liver cancer.Methods Patients with unresectable localized liver cancer were selected as the research objects.They were randomly divided into the control group and the observation group.The ob-servation group was treated with sorafenib toluene sulfonate combined with TACE,and the control group was treated with TACE a-lone.The clinical efficacy,the level of tumor markers[alpha fetoprotein(AFP),carbohydrate antigen(CA19-9)],the level of liv-er function indicators[alanine aminotransferase(ALT),total bilirubin(TBIL),albumin(ALB)]and the incidence of adverse re-actions were compared between the 2 groups.Results The objective remission rate was 33.33%in the control group and 54.17%in the observation group,the difference was statistically significant(P<0.05).The disease control rate was62.50%in the control group and 87.50%in the observation group,the difference was statistically significant(P<0.05);The levels of AFP,CA19-9,ALT,Tbil and Alb in the control group were significantly lower than those in the control group(P<0.05).Adverse reac-tion of the 2 groups had no statistical difference(P<0.05).Conclusion Sorafenib tosylate combined with TACE has a better clinical effect in patients with unresectable localized liver cancer,with less damage to liver function and no increase in adverse re-actions,which is safer and more reliable.
万方数据
维普
